The manufacturers are all small companies in the U.S. There's no General Electric for ECT devices.
That option would give ECT devices a pass and ensure that they remain available to doctors.
There are 100, 000 people who undergo ECT in the U.S., and it won't be available to them.
The report noted that among energy companies, ECT shares displayed both attractive valuation metrics and strong profitability metrics.
FORBES: ECT Added as Top 10 Energy Dividend Stock With 11.16% Yield
Below is a long-term dividend history chart for ECT, which Dividend Channel stressed as being of key importance.
FORBES: ECT Added as Top 10 Energy Dividend Stock With 11.16% Yield
Below is a long-term dividend history chart for ECT, which the report stressed as being of key importance.
FORBES: This Stock Has A 14.42% Yield And Sells For Less Than Book
The report noted that among the coverage universe, ECT shares displayed both attractive valuation metrics and strong profitability metrics.
FORBES: This Stock Has A 14.42% Yield And Sells For Less Than Book
The association supports reclassifying ECT devices as medium risk, which would preclude the need for additional research regarding their safety and effectiveness.
Sony is refining what we can do, (Dust514), while Microsoft is refining how we can pay, (DRM, banned accounts, one time use codes, ect).
The FDA's official decision will not be made for at least a year, and doctors can continue to use ECT devices in the interim.
Not that you CANT get to max level with basic bags, its that at SOME point going to need that bag space, bank space, ect.
Apple needs to innovate, live tiles, better integration with apps ect.
On Friday, a majority of experts on the panel expressed support for classifying ECT devices as high risk for the treatment of depression and several other conditions.
But because ECT devices were already in use when the FDA put those rules in place about 35 years ago, they were exempted from the approval process.
On the other side, patients' rights organizations and advocacy groups such as the Depression and Bipolar Support Alliance (DBSA) have urged the FDA not to hastily reclassify ECT devices.
On Thursday, a Food and Drug Administration (FDA) advisory panel will meet to consider whether the machines used in ECT should be more tightly regulated than they are now.
The agency can leave ECT devices in their current class and require manufacturers to provide evidence of safety and effectiveness, which may entail new clinical trials and could temporarily limit the devices' use.
If the FDA follows the panel's advice, as it usually does, the makers of ECT devices may need to provide the agency with additional safety and efficacy evidence, like that required for prescription drugs.
"It may be a major disaster, " says Max Fink, MD, a professor emeritus of psychiatry and neurology at Stony Brook University Medical Center, in New York, who researched and performed ECT for 45 years.
Just two small companies in the U.S. make ECT devices, and some experts worry that neither will have the resources to conduct the studies that the FDA may require, which could ultimately restrict access to the treatment.
For decades psychiatrists have used shock therapy to treat cases of depression that haven't been helped by antidepressant medications, and in recent years the treatment -- now known as electroconvulsive therapy (ECT) -- has experienced something of a revival.
Nancy Koenigsberg, the legal director of Disability Rights New Mexico, in Albuquerque, New Mexico, one of many patient advocacy groups that argued for stricter oversight of ECT devices in the lead-up to last week's meeting, says her organization was "pleased" with the outcome.
The American Psychiatric Association (APA) and scores of individual psychiatrists have expressed support for permanently easing the restrictions on ECT devices, because they worry that manufacturers of ECT devices may lack the funds, time, or motivation to meet new FDA requirements (by conducting new research, for instance).
应用推荐